Clinical Trials & Research
Makis Health Clinic is not just a treatment facility; it is a global research hub. We are dedicated to advancing the field of Nuclear Medicine by actively participating in and leading clinical trials to bring the next generation of theranostics to our patients faster than traditional pathways.
Active Clinical Trials
We are currently enrolling patients in several early and late-phase clinical trials designed to evaluate the safety and efficacy of novel radiotracers and alpha-emitting isotopes.
Ac-225 DOTATATE in Refractory NETs
RecruitingEvaluating the efficacy of Targeted Alpha Therapy (TAT) using Actinium-225 in patients with advanced neuroendocrine tumors who have progressed after standard Lutetium-177 PRRT therapy.
Key Eligibility:
- Confirmed progression on Lu-177 DOTATATE
- Positive Ga-68 DOTATATE PET/CT uptake
- Adequate renal and hepatic function
Lu-177 PSMA + PARP Inhibitor Synergy
Active, Not RecruitingInvestigating the synergistic effects of combining PARP inhibitors (to prevent cancer cell DNA repair) with Lutetium-177 PSMA-617 beta-radiation in metastatic castration-resistant prostate cancer.
This cohort is fully enrolled. Interim data analysis expected Q3 2026.
Ac-225 FAPI in Advanced Solid Tumors
RecruitingA Phase I/II trial exploring Fibroblast Activation Protein Inhibitor (FAPI) targeted alpha therapy. FAP is overexpressed in the tumor microenvironment of over 28 different cancers (including breast, colon, and pancreatic).
Key Eligibility:
- Refractory solid tumor malignancy
- Positive Ga-68 FAPI PET/CT uptake
Trial Screening
Not all patients are eligible for clinical trials. Eligibility is strictly governed by institutional review boards (IRBs) to ensure patient safety. The first step to determining eligibility is a comprehensive review of your medical records and baseline molecular imaging.
Request Trial ScreeningScientific Publications
Our medical team, led by Dr. William Makis, has authored over 100 peer-reviewed publications shaping the future of targeted cancer treatments.
Journal of Nuclear Medicine • 2024
Efficacy of Targeted Alpha Therapy (Ac-225 PSMA) in Heavily Pre-Treated mCRPC
A retrospective analysis of 50 patients showing significant PSA decline and improved overall survival in a salvage setting.
European Journal of Nuclear Medicine • 2023
Dosimetry and Renal Toxicity Profiles in Lutetium-177 DOTATATE PRRT
Evaluating the long-term renal safety of repeated PRRT cycles using advanced renoprotective amino acid infusions.
Clinical Cancer Research • 2025
The Abscopal Effect in Radioligand Therapy: Immune System Activation
Investigating how localized alpha radiation damage to tumors stimulates systemic anti-tumor immunity.
Theranostics • 2022
Emerging Targets: Ga-68 FAPI PET/CT in Evaluating Metastatic Breast Cancer
A pilot study comparing FAPI uptake to standard FDG PET in mapping difficult-to-detect breast cancer lesions.